FLUZALP™ Quadrivalent is an inactivated Influenza vaccine indicated for active immunization against Influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUZALP QUADRIVALENT is approved for use in persons 4 years of age and older.
The quadruple strain formula provides protection for up to 6 months*. The product’s dosage form is injection, suspension and is administered via intramuscular form.
Recombinant DNA Technology:
Our Vaccines, including FLUZALP are produced using state of the art vaccine production technology of Recombinant DNA. These Vaccines carry their surface protein called Hemagglutinin (HA) which is the notorious property of a flu virus that activates the Human Immune Response to create antibodies that are targeted towards that Virus.
This Recombinant DNA is then introduced into a cell line which sets off a chain reaction by instructing the cell to produce these Hemagglutinin Antigen which is then collected and processed in order to be packaged as a recombinant flu vaccine. Each batch of these vaccines is then tested by the relevant regulatory authority for Quantity, Quality and Efficacy before being release into the market. The result of using this technology is that is the hemagglutinin antigen cannot adapt of mutate, and that it avoids changes in hemagglutinin antigen structure that can lead to reduced vaccine effectiveness.
FLUZALP Quadrivalent is a vaccine manufactured by a company established in 1961, with experience in manufacturing over 1,000 pharmaceuticals and Nutraceuticals. One of the major advantages of buying from Davati Medical is time to market. Our factories has the ability to manufacture vaccines in larger volume and deliver them in 30-60 days, depending on volume and production availability.
*Data on file.
**Fluzalp is not available for sale or use within the United States**